Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

746704

registered interest
date	29/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Sugar
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the oral contribution by the former Under-Secretary of State for Health on 21 March 2017, Official Report, Column 775, what assessment he has made of the effect of the Food and Drink Federation's decision not to introduce the Government's 20 per cent optional reduction in sugar content in its members' products by 2020 on his Department's policies to tackle (a) childhood obesity and (b) childhood tooth decay.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	2048
answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>There has been no assessment made of the effect of Food and Drink Federation members’ compliance or non-compliance in achieving the 20% reduction in sugar content of key products contributing to children’s intakes by 2020 on childhood obesity or childhood tooth decay.</p><p> </p><p>In ‘Sugar reduction: The evidence for action’, published in October 2015, Public Health England (PHE) undertook modelling work to estimate the potential health impact and wider economic benefits of achieving the average population intake recommendation for sugar. This modelling found that achieving this over a 10-year period would result in 4,100 premature deaths and 204,000 cases of dental caries being averted, resulting in a total cost saving to the National Health Service of £484 million.</p><p> </p><p>PHE encourages all businesses to achieve the reductions in sugar as set out in ‘Childhood obesity: a plan for action’. A detailed assessment of industry’s progress will be published in March 2018.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/07/2017 11:13:15 answering member 4067 label Biography information for Steve Brine
tabling member	298 label Biography information for Steve McCabe

746734

registered interest
date	29/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Air Pollution: Death
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate his Department has made of the total number of premature deaths attributable to air pollution in the last 12 months; and if he will make a statement.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	1938
answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>There is no estimate of the total number of premature deaths attributable to air pollution.</p><p> </p><p>The air pollution health indicator 3.01 in the Public Health Outcomes Framework estimates the fraction of adult mortality attributable to long-term exposure to PM2.5 air pollution (in local authority areas) in England. This ranges from less than 3% in the least polluted rural areas to over 7% in some London boroughs.</p><p> </p><p>In 2015, the average for England was 4.7%. This is equivalent to approximately 25,000 adult deaths attributable to fine particulate matter exposure (PM2.5) in England every year.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/07/2017 14:34:48 answering member 4067 label Biography information for Steve Brine
tabling member	308 label Biography information for Mr Jim Cunningham

746815

registered interest
date	29/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Smoking
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps the Government plans to take to ensure that smoking rates among pregnant women fall.
tabling member constituency	Colchester
tabling member printed	Will Quince
uin	2014
answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>The Government is developing a new tobacco control plan, which will be published shortly. The plan will contain actions to reduce the prevalence of smoking during pregnancy.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/07/2017 11:00:17 answering member 4067 label Biography information for Steve Brine
tabling member	4423 label Biography information for Will Quince

746852

registered interest
date	29/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Salmonella
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many cases of salmonella were identified in (a) 2014, (b) 2015, (c) 2016, and (d) 2017; and of those cases how many originated in each non-UK EU country.
tabling member constituency	North Antrim
tabling member printed	Ian Paisley
uin	2202
answer	answer is ministerial correction date of answer 06/07/2017 answer text <p>Confirmed cases of non-typhoidal Salmonella in England are reported on the laboratory reporting database called Second Generation Surveillance System. The total number of cases reported for 2014 to the first quarter of 2017 (1 January 2017 to 31 March) are included in the following table.</p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>Number of cases</p></td></tr><tr><td><p>2014</p></td><td><p>6,939</p></td></tr><tr><td><p>2015</p></td><td><p>8,185</p></td></tr><tr><td><p>2016</p></td><td><p>8,248</p></td></tr><tr><td><p>2017 (1<sup>st</sup> quarter)*</p></td><td><p>1,419</p></td></tr></tbody></table><p>*Data available for 1 January to 31 March 2017</p><p> </p><p>Note: data for 2015, 2016 and 2017 is still undergoing validation and therefore may change prior to publication.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 06/07/2017 15:45:42 answering member 4067 label Biography information for Steve Brine attachment 1 file name PQ2202 attached table.docx title PQ2202 attached table
tabling member	4129 label Biography information for Ian Paisley

746916

registered interest
date	29/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	HIV Infection: Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to Public Health England's announcement of 20 June 2017 on the HIV PrEP Impact trial in England, what steps are being taken to ensure that high-risk patients are able to access the trial outside London, Manchester and Brighton.
tabling member constituency	Hazel Grove
tabling member printed	Mr William Wragg
uin	2009
answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>The HIV pre-exposure prophylaxis (PrEP) Impact trial will seek to engage as many of the approximately 230 genitourinary medicine clinics in England as possible. All clinics will be offered the opportunity to participate, regardless of where they are situated. In keeping with the open access nature of sexual health services, patients will be able to attend any clinic in England that is participating in the trial and therefore have their trial eligibility assessed regardless of where they live.</p><p> </p><p>NHS England and Public Health England have stated that the trial will begin by the summer of 2017, available to view here:</p><p><a href="https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england" target="_blank">https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england</a></p><p> </p><p>The final timescale will be considered at the July meeting of the PrEP Programme Oversight Board (POB) when updated information on the likely timeline of availability of trial drug at trial sites will be provided. Several bids to supply the trial drug were received on the June 29 deadline. If the trial timeline needs to change, new information will be provided in the Stakeholder Update due to be issued after the July 14 PrEP POB.</p><p> </p><p>The Frequently Asked Questions will be published following review at the July meeting of the PrEP POB.</p><p> </p><p>The PrEP Impact trial application was submitted to the Research Ethics Committee (REC) at the end of June. The committee will issue a final ethical opinion within 60 days. The current expectation is that approval will be obtained in time for the drug becoming available. The REC approval timeline is independent of the trial drug procurement process.</p><p> </p><p>Before a trial site can begin to recruit patients, they must provide confirmation of capacity and capability to the Trial co-ordination centre and the timescales for this can vary across localities. This process includes negotiating and finalising local trial contracts and having site staff undergo trial-specific training provided by the Trial co-ordination centre (St Stephen’s Clinical Research). This process will occur in parallel to obtaining national ethics approval and the trial drug procurement activities. Some sites may be in a position to begin trial participant recruitment as soon as the trial drug becomes available.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 2010 2011 2012 2013 question first answered 04/07/2017 11:10:26 answering member 4067 label Biography information for Steve Brine
tabling member	4429 label Biography information for Mr William Wragg

746917

registered interest
date	29/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	HIV Infection: Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to Public Health England's announcement of 20 June 2017 on the HIV PrEP Impact trial in England, when the timeline for the next steps of the trial referred to in the announcement will be published.
tabling member constituency	Hazel Grove
tabling member printed	Mr William Wragg
uin	2010
answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>The HIV pre-exposure prophylaxis (PrEP) Impact trial will seek to engage as many of the approximately 230 genitourinary medicine clinics in England as possible. All clinics will be offered the opportunity to participate, regardless of where they are situated. In keeping with the open access nature of sexual health services, patients will be able to attend any clinic in England that is participating in the trial and therefore have their trial eligibility assessed regardless of where they live.</p><p> </p><p>NHS England and Public Health England have stated that the trial will begin by the summer of 2017, available to view here:</p><p><a href="https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england" target="_blank">https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england</a></p><p> </p><p>The final timescale will be considered at the July meeting of the PrEP Programme Oversight Board (POB) when updated information on the likely timeline of availability of trial drug at trial sites will be provided. Several bids to supply the trial drug were received on the June 29 deadline. If the trial timeline needs to change, new information will be provided in the Stakeholder Update due to be issued after the July 14 PrEP POB.</p><p> </p><p>The Frequently Asked Questions will be published following review at the July meeting of the PrEP POB.</p><p> </p><p>The PrEP Impact trial application was submitted to the Research Ethics Committee (REC) at the end of June. The committee will issue a final ethical opinion within 60 days. The current expectation is that approval will be obtained in time for the drug becoming available. The REC approval timeline is independent of the trial drug procurement process.</p><p> </p><p>Before a trial site can begin to recruit patients, they must provide confirmation of capacity and capability to the Trial co-ordination centre and the timescales for this can vary across localities. This process includes negotiating and finalising local trial contracts and having site staff undergo trial-specific training provided by the Trial co-ordination centre (St Stephen’s Clinical Research). This process will occur in parallel to obtaining national ethics approval and the trial drug procurement activities. Some sites may be in a position to begin trial participant recruitment as soon as the trial drug becomes available.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 2009 2011 2012 2013 question first answered 04/07/2017 11:10:26 answering member 4067 label Biography information for Steve Brine
tabling member	4429 label Biography information for Mr William Wragg

746918

registered interest
date	29/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	HIV Infection: Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to Public Health England's announcement of 20 June 2017 on the HIV PrEP Impact trial in England, when the frequently asked questions document referred to in the announcement will be published.
tabling member constituency	Hazel Grove
tabling member printed	Mr William Wragg
uin	2011
answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>The HIV pre-exposure prophylaxis (PrEP) Impact trial will seek to engage as many of the approximately 230 genitourinary medicine clinics in England as possible. All clinics will be offered the opportunity to participate, regardless of where they are situated. In keeping with the open access nature of sexual health services, patients will be able to attend any clinic in England that is participating in the trial and therefore have their trial eligibility assessed regardless of where they live.</p><p> </p><p>NHS England and Public Health England have stated that the trial will begin by the summer of 2017, available to view here:</p><p><a href="https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england" target="_blank">https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england</a></p><p> </p><p>The final timescale will be considered at the July meeting of the PrEP Programme Oversight Board (POB) when updated information on the likely timeline of availability of trial drug at trial sites will be provided. Several bids to supply the trial drug were received on the June 29 deadline. If the trial timeline needs to change, new information will be provided in the Stakeholder Update due to be issued after the July 14 PrEP POB.</p><p> </p><p>The Frequently Asked Questions will be published following review at the July meeting of the PrEP POB.</p><p> </p><p>The PrEP Impact trial application was submitted to the Research Ethics Committee (REC) at the end of June. The committee will issue a final ethical opinion within 60 days. The current expectation is that approval will be obtained in time for the drug becoming available. The REC approval timeline is independent of the trial drug procurement process.</p><p> </p><p>Before a trial site can begin to recruit patients, they must provide confirmation of capacity and capability to the Trial co-ordination centre and the timescales for this can vary across localities. This process includes negotiating and finalising local trial contracts and having site staff undergo trial-specific training provided by the Trial co-ordination centre (St Stephen’s Clinical Research). This process will occur in parallel to obtaining national ethics approval and the trial drug procurement activities. Some sites may be in a position to begin trial participant recruitment as soon as the trial drug becomes available.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 2009 2010 2012 2013 question first answered 04/07/2017 11:10:26 answering member 4067 label Biography information for Steve Brine
tabling member	4429 label Biography information for Mr William Wragg

746919

registered interest
date	29/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	HIV Infection: Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to Public Health England's announcement of 20 June 2017 on the HIV PrEP Impact trial in England, how long he expects it will take to receive approval from the Research Ethics Committee once the drug procurement contract for the trial has been agreed.
tabling member constituency	Hazel Grove
tabling member printed	Mr William Wragg
uin	2012
answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>The HIV pre-exposure prophylaxis (PrEP) Impact trial will seek to engage as many of the approximately 230 genitourinary medicine clinics in England as possible. All clinics will be offered the opportunity to participate, regardless of where they are situated. In keeping with the open access nature of sexual health services, patients will be able to attend any clinic in England that is participating in the trial and therefore have their trial eligibility assessed regardless of where they live.</p><p> </p><p>NHS England and Public Health England have stated that the trial will begin by the summer of 2017, available to view here:</p><p><a href="https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england" target="_blank">https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england</a></p><p> </p><p>The final timescale will be considered at the July meeting of the PrEP Programme Oversight Board (POB) when updated information on the likely timeline of availability of trial drug at trial sites will be provided. Several bids to supply the trial drug were received on the June 29 deadline. If the trial timeline needs to change, new information will be provided in the Stakeholder Update due to be issued after the July 14 PrEP POB.</p><p> </p><p>The Frequently Asked Questions will be published following review at the July meeting of the PrEP POB.</p><p> </p><p>The PrEP Impact trial application was submitted to the Research Ethics Committee (REC) at the end of June. The committee will issue a final ethical opinion within 60 days. The current expectation is that approval will be obtained in time for the drug becoming available. The REC approval timeline is independent of the trial drug procurement process.</p><p> </p><p>Before a trial site can begin to recruit patients, they must provide confirmation of capacity and capability to the Trial co-ordination centre and the timescales for this can vary across localities. This process includes negotiating and finalising local trial contracts and having site staff undergo trial-specific training provided by the Trial co-ordination centre (St Stephen’s Clinical Research). This process will occur in parallel to obtaining national ethics approval and the trial drug procurement activities. Some sites may be in a position to begin trial participant recruitment as soon as the trial drug becomes available.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 2009 2010 2011 2013 question first answered 04/07/2017 11:10:26 answering member 4067 label Biography information for Steve Brine
tabling member	4429 label Biography information for Mr William Wragg

746920

registered interest
date	29/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	HIV Infection: Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to Public Health England's announcement of 20 June 2017 on the HIV PrEP Impact trial in England, how long he expects genitourinary medicine clinics and trial sites to take to prepare in readiness for the trial once the drug procurement contract for the trial has been agreed.
tabling member constituency	Hazel Grove
tabling member printed	Mr William Wragg
uin	2013
answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>The HIV pre-exposure prophylaxis (PrEP) Impact trial will seek to engage as many of the approximately 230 genitourinary medicine clinics in England as possible. All clinics will be offered the opportunity to participate, regardless of where they are situated. In keeping with the open access nature of sexual health services, patients will be able to attend any clinic in England that is participating in the trial and therefore have their trial eligibility assessed regardless of where they live.</p><p> </p><p>NHS England and Public Health England have stated that the trial will begin by the summer of 2017, available to view here:</p><p><a href="https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england" target="_blank">https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england</a></p><p> </p><p>The final timescale will be considered at the July meeting of the PrEP Programme Oversight Board (POB) when updated information on the likely timeline of availability of trial drug at trial sites will be provided. Several bids to supply the trial drug were received on the June 29 deadline. If the trial timeline needs to change, new information will be provided in the Stakeholder Update due to be issued after the July 14 PrEP POB.</p><p> </p><p>The Frequently Asked Questions will be published following review at the July meeting of the PrEP POB.</p><p> </p><p>The PrEP Impact trial application was submitted to the Research Ethics Committee (REC) at the end of June. The committee will issue a final ethical opinion within 60 days. The current expectation is that approval will be obtained in time for the drug becoming available. The REC approval timeline is independent of the trial drug procurement process.</p><p> </p><p>Before a trial site can begin to recruit patients, they must provide confirmation of capacity and capability to the Trial co-ordination centre and the timescales for this can vary across localities. This process includes negotiating and finalising local trial contracts and having site staff undergo trial-specific training provided by the Trial co-ordination centre (St Stephen’s Clinical Research). This process will occur in parallel to obtaining national ethics approval and the trial drug procurement activities. Some sites may be in a position to begin trial participant recruitment as soon as the trial drug becomes available.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 2009 2010 2011 2012 question first answered 04/07/2017 11:10:26 answering member 4067 label Biography information for Steve Brine
tabling member	4429 label Biography information for Mr William Wragg

746921

registered interest
date	29/06/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services: Dudley
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what (a) penalties or (b) compensation would apply in the event of early termination of the contract for Dudley's multi-speciality community provider.
tabling member constituency	Dudley North
tabling member printed	Ian Austin
uin	2023
answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>The commissioner – in this case Dudley Clinical Commissioning Group (CCG) – is solely responsible for carrying out the procurement and it will be for the commissioner to determine break points, penalties, compensation and arrangements to ensure continuity of service.</p><p> </p><p>As with all standard National Health Service contracts, we would expect any multi-speciality community provider (MCP) contract to set out the circumstances in which the contract may be terminated by either party and the process following termination. It will be for the CCG to determine where the break points should be, factoring in the potential impacts on value for money. In accordance with the existing terms of the NHS Standard Contract, there will be a 12 month no fault termination clause.</p><p> </p><p>The Dudley MCP contract will ensure that in the event of a provider not meeting their obligations, and where there is a need for an early termination, the provider will be required to pay the commissioners any additional costs and expenses incurred as a result of the termination. This will include those incurred in recommissioning the services covered by the contract from an alternative provider for the rest of the term of the contract as well as ensuring service continuity.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 2022 2024 question first answered 04/07/2017 14:41:22 answering member 4067 label Biography information for Steve Brine
tabling member	1511 label Biography information for Lord Austin of Dudley